FF Pharma
Utrecht, Utrecht, The Netherlands
About FF Pharma
FF Pharma, a biopharmaceutical company, develops anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The functions of CD40 in immune regulation suggest that the CD40 pathway may play a role in diseases in which anomalous immune responses, e.g. autoantibody production or chronic inflammation, are a feature.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $5.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2013)
- Website: ffpharma.com
- Phone: +32 11 286917
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/ff-pharma-2491559 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.